Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy

• Published in: International journal of infectious diseases Vol. 56; no. C; pp. 136 - 139
• Main Authors: Nagu, Tumaini, Aboud, Said, Rao, Martin, Matee, Mecky, Axelsson, Rebecca, Valentini, Davide, Mugusi, Ferdinand, Zumla, Alimuddin, Maeurer, Markus
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.03.2017; Elsevier
• Subjects: Adult; Antitubercular Agents - pharmacology; Antitubercular Agents - therapeutic use; cellular immune response; CMV; Cytomegalovirus - immunology; EBV; Female; Herpesvirus 4, Human - immunology; Humans; IFN-γ; Immunity, Cellular - immunology; Infectious Disease; Male; Predictive Value of Tests; pulmonary tuberculosis; Pulmonary/Respiratory; survival; TB therapy; Treatment Outcome; Tuberculosis Vaccines - immunology; Tuberculosis, Pulmonary - drug therapy; Tuberculosis, Pulmonary - immunology; Tuberculosis, Pulmonary - mortality; pulmonary tuberculosis; cellular immune response; IFN-γ; TB therapy; survival; EBV; CMV

•CMV, EBV and ESAT-6 – specific IFN-γ responses in patients with pulmonary TB at diagnosis correlate with cure and survival during anti-TB therapy.•CMV/EBV responses maybe good biomarkers to identify patients at high risk to succumb to TB disease.•CVM/EBV-vectored vaccines are recommended for future...